ClinicalTrials.gg
Not yet recruitingNCT05961670Updated Jul 27, 2023

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

An observational study in Respiratory Distress Syndrome, Newborn, sponsored by Keck School of Medicine of USC. Not yet recruiting at 1 site in United States. Open to participants aged 1 Hour to 24 Hours. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Keck School of Medicine of USC · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
1 Hour to 24 Hours
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Respiratory Distress Syndrome, Newborn · United States.

Started
2023
with 1 other
Observational
5 of 34
2 open now
Registered
29th of 34
by date
Lead sponsor
2 of 34
Keck School of Medicine of USC

Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, this one is one of 2 that started in 2023, is one of 5 observational ones, and was the 29th registered.

Respiratory Distress Syndrome, Newborn

123 studies on the registry are indexed under Respiratory Distress Syndrome, Newborn; 24 are open to participants now.

Browse Respiratory Distress Syndrome, Newborn studies →

Open to participants now

5 of the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Respiratory Distress Syndrome, Newborn studies recruiting now, 2 (17%) set no upper age limit and 10 (83%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: 1 Hour to 24 Hours · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, or all of them as a file.
02

Study summary

Premature infants are more likely to develop hypoxemia after birth often requiring invasive and Non-Invasive Mechanical ventilation and surfactant therapy to improve alveolar gas exchange and oxygen transport. Near-infrared spectroscopy (NIRS) has been used to detect pulmonary regional oxygen saturation (rpSO 2 ) as well as cerebral regional oxygen saturation (rcSO2 ) and evaluate the oxygenation state of the lung and brain. This is a prospective observational study to evaluate utility of rpSO2 and compare it with rcSO2 in preterm infants born between 23-32 weeks of gestation receiving noninvasive ventilation and surfactant treatment. Enrolled patients will be continuously studied with placement of NIRS monitor using cerebral sensor (INVOS™) for 6 hrs and 15 min before and after surfactant administration. Pulmonary regional oxygen saturation (rpSO2) with a sampling interval of 6 s will be followed for 6hrs.

03

Conditions studied

  • Respiratory Distress Syndrome, Newborn
04

Who can participate

Ages eligible
1 Hour to 24 Hours
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Inborn premature infants

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Infants born between 23-32 weeks of gestation admitted to the Neonatal Intensive Care Unit with respiratory distress receiving non-invasive ventilation and requiring Surfactant Replacement Therapy.

Exclusion criteria

Exclusion Criteria:

Neonates with no need for respiratory support/Surfactant. Neonates with congenital malformations.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • DeviceNeer Infrared Spectroscopy

    Premature infants will be studied with brain and lung NIRS before and after surfactant administration

06

What researchers measure

Primary outcomes

  1. rpSO2 before and after surfactant therapy

    brain and lung rpSO2 will be compared before and after surfactant administration

    Time frame: 6 hours

Secondary outcomes

  1. variations on rpSO2 and rcSO2 during changes in ventilation modes

    Will evaluate for variations with various ventilation modes

    Time frame: 6 hours

  2. correlation between rpSO2L and SpO2/FiO2 ratio, a/APO2, and O.I

    Correlation will be assessed between rpSO2 and other ratios

    Time frame: 6 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2023; primary completion for Jun 2024, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2023
First posted
Jul 27, 2023
StartEst.
Aug 1, 2023
Primary completionEst.
Jun 30, 2024
CompletionEst.
Sep 30, 2024
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05961670
Lead sponsor
Keck School of Medicine of USC
Collaborators
Medtronic
Responsible party
Manoj Biniwale (Associate Professor of Pediatrics, Keck School of Medicine of USC) — Principal investigator
First posted
Jul 27, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Jun 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Jul 27, 2023

Study contacts

Manoj Biniwale, MD
Contact
Biniwale@usc.edu
3234093406
Rangasamy Ramanathan, MD
Contact
Ramanath@usc.edu
3234093406

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion